-
Endpoints News2 weeks ago
CHMP recommends subcutaneous form of Sanofi’s Sarclisa and four new drugs
The European Medicines Agency’s human medicines committee has recommended the approval of four new drugs and a new form of Sanofi’s multiple myeloma drug. CHMP gives...
-
STAT News – Biotech2 weeks agoSTAT+: In private meetings, White House works to win pharma companies’ support for drug pricing bill
WASHINGTON — The White House has drafted legislative text for its drug pricing policy, and officials are in the process of sharing it with more than...
-
Uncategorized2 weeks agoOtsuka picks up PTSD drug with $700M Transcend buy
The buyout, which includes another $525 million in floated payouts, hands Otsuka a medicine it sees as a possibly “paradigm-shifting therapy” in psychiatry.
-
GEN – Genetic Engineering & Biotechnology News2 weeks ago
Agentic AI, Virtual Cell, LNP Vaccine Boosters, Engineered Organs, and Mergers
This week, agentic AI steps into the limelight buoyed by the momentum from generative AI. And there’s a new virtual cell model in town courtesy of AI-drug developer Xaira Therapeutics. From...
-
GEN – Genetic Engineering & Biotechnology News2 weeks ago
Lonza Media Development Lab Set Up in Singapore
Lonza launched a media development lab at its Singapore site to support bioprocessing clients in optimizing their media formulations and facilitating a transition to GMP manufacturing....
-
BioPharma Dive – AI / Data2 weeks agoAstraZeneca lung drug gets ‘surprise’ win in COPD trials
The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent.
-
Endpoints News2 weeks ago
AnaptysBio spins out biotech operations; Affibody’s data in hidradenitis suppurativa
Plus, news about Zenas and Ysios Capital: 🌀 AnaptysBio’s spinout: The independent public company, called First Tracks Biotherapeutics, is expected to start trading on April 20....
-
BioPharma Dive – AI / Data2 weeks agoNovartis targets Xolair successor in buyout of startup Excellergy
Worth up to $2 billion, the deal is centered around a drug that could lead to faster and more complete control of allergic conditions than Novartis...
-
Endpoints News2 weeks ago
FDA approves Rocket’s gene therapy for ultra-rare immune disease
A rare disease gene therapy from Rocket Pharmaceuticals has garnered FDA approval after an earlier rejection for manufacturing problems. The FDA on Thursday granted accelerated approval...
-
GEN – Genetic Engineering & Biotechnology News2 weeks agoStem Cells at the Frontier: Breakthroughs, Barriers, and What’s Next
Register Now Panelists: Robert Signer, PhD Associate Professor, MedicineUniversity of California San Diego View Bio Panelist Robert Signer, PhD Robert Signer, PhD, is a stem cell...
Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis
